ATAD3A and head and neck squamous cell carcinoma: These novel findings signify that the impairment of ATAD3A-mediated mitochondrial oncogenic signaling could be a potential therapeutic approach, which may further combine with RAS inhibition to achieve synergistic anti-HNSCC efficacy.